News Center

Home page

Peak Report

News reports

The 12th meeting of the 11th board of directors and the 11th meeting of the 10th board of supervisors held to review and approve the annual work report and other relevant proposals

Release time:

2023-04-21

General Manager's report pointed out that in 2022, my country's macroeconomic policy will adhere to the general tone of seeking progress while maintaining stability. The annual GDP was 121.02 trillion billion yuan, an increase of 3.0 percent over last year (data source: National Bureau of Statistics). Centering on the general policy of "reform, breakthrough, innovation and development", the company strives to maintain the orderly development of various production and operation work, achieving operating income of 3.56 billion yuan for the whole year, a decrease of 6.43 percent over the same period last year, and net profit attributable to shareholders of 0.288 billion yuan, a decrease of 68.86 percent over the same period last year. By the end of 2022, the company's total assets were 7.321 billion billion yuan, up 4.22 percent year-on-year, and the net assets attributable to shareholders of listed companies were 5.186 billion billion yuan, down 0.41 percent year-on-year.

2022

, the company's industrial chain extension war made new progress. The company set up Yunnan Jianfeng New Building Materials Co., Ltd. to promote its aggregate, machine sand and other projects in an orderly manner, and Yunnan Jianfeng invested 0.133 billion yuan to increase the capital of its subsidiary Jianfeng Exhibition, making it a holding enterprise of the company, and the company's cement business sector has been further developed.

Facing the unfavorable external environment, the company's cement companies continue to implement benchmarking and refined management, steadily implement various technical reforms, strictly control production costs, strive to overcome the pressure of declining demand, and actively expand the sales market. Daye Peak has improved the overall production capacity of the kiln system through technical transformation and operation process optimization of grate cooler, packaging machine and kiln cylinder, combined with the use of MES system for optimal parameter traceability. Actively develop new agents, open up new markets, strengthen cooperation with large enterprises, undertake key projects, effectively cope with the overall weak cement market and maintain the balance of production and sales; vigorously promote the construction of green mines and green factories, and successfully entered the list of national green factories in 2022. Yunnan Jianfeng has strengthened the technological transformation of energy saving and consumption reduction, reformed the kiln head sealing device, grate cooler and other equipment, and improved the kiln output. The dust collector at the bottom of the cement blending warehouse has been added, and the feeding device of the roller press has been reformed, effectively improving the production site environment. Actively implement the brand strategy, adhere to the "direct sales + agent" dual-track sales model, while effectively reducing the sales cost while maintaining the advantages of multi-channel sales. Huang Ping Jianfeng actively studied, explored and applied advanced technology to tackle key problems. Through the transformation of the cone under the decomposition furnace to reduce negative pressure fluctuation, replace the high-temperature feed lock valve, and increase the snowman pushing device of the grate cooler, the stability of the equipment has been improved. Facing the unfavorable demand situation, it actively undertakes key projects externally and strengthens the business skills training of the marketing team internally, with Kaili and Huang Ping as the core markets, maintain the leading sales of the same type of kiln line in the region.

2022

, the company's pharmaceutical sector technical reform and engineering construction continued to advance, innovation and research and development to make new progress. Jianfeng Pharmaceutical's annual production of 2 billion tablets of solid preparations (international project) has completed the completion acceptance of construction projects, equipment installation and debugging, certified product registration batch production, completed the human bioequivalence test, submitted registration materials, and entered the waiting stage of cGMP application for certification; jinxi Production Base has completed the completion and acceptance of the technical transformation project of bulk drugs, completed the installation and debugging of the newly added RTO incineration treatment facilities, completed the automatic transformation of the packaging equipment of freeze-dried powder injection and solid preparation production line, and completed the transformation of the refrigeration system of the raw material workshop and the comprehensive preparation building. The construction of the single-dose eye drop production line of Jianfeng Pharmaceutical has also been basically completed and has entered the stage of product stability inspection. The 205 and 206 workshops of Anhui Xinbeika Phase II Project have been completed and put into trial production. The chlorine dioxide workshop has completed the information control transformation and improved the safety guarantee level. The technical renovation project of Moxi Xiaohuan and pharmaceutical intermediates in Jianfeng Beika 102 Workshop has been completed and put into trial operation. The 203, 205 and 206 workshops have been completed and have entered the stage of production plan review. Jianfeng Pharmaceutical and its subsidiaries further increased investment in research and development, continued to promote the phase I clinical trials of the new anti-tumor drug DPT and JFAN-1001 project, and completed the application for production registration of several products such as fluprost eye drops, single-dose sodium hyaluronate eye drops, and mycophenolate mofetil capsules. At present, 11 drugs (including consistency evaluation) have been submitted to the State Drug Administration for production registration.

On the same day, the company also held the 11th meeting of the 10th Board of Supervisors, and reviewed and approved 5 related reports and proposals including the 2022 Board of Supervisors Report of the company. (residual fruit)

More information

The company fully deploys 2018 work

On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals

2020

07-30

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise

On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.

2020

07-31

Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base

2020

07-31

The company was rated as an advanced unit of the city's focus on talent and love talent.

News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)

2020

07-31

< 1...38 39 40...61 > 跳转到页